Subscribe To
Arena pharmaceuticals, inc. (arna) ceo amit munshi on q3 2021 results - earnings call transcript
Arena pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript...
November 4, 2021, 11:07 pm
Arena pharmaceuticals, inc. (arna) ceo amit munshi on q3 2021 results - earnings call transcript
Arena pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript...
November 4, 2021, 11:07 pm
Arena pharmaceuticals, inc. (arna) ceo amit munshi on q3 2021 results - earnings call transcript
Arena pharmaceuticals, Inc. (ARNA) CEO Amit Munshi on Q3 2021 Results - Earnings Call Transcript...
November 4, 2021, 11:07 pm
Regeneron pharmaceuticals, inc. (regn) ceo leonard schleifer on q3 2021 results - earnings call transcript
Regeneron pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcr...
November 4, 2021, 1:49 pm
Regeneron pharmaceuticals, inc. (regn) ceo leonard schleifer on q3 2021 results - earnings call transcript
Regeneron pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcr...
November 4, 2021, 1:49 pm
Regeneron pharmaceuticals, inc. (regn) ceo leonard schleifer on q3 2021 results - earnings call transcript
Regeneron pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q3 2021 Results - Earnings Call Transcr...
November 4, 2021, 1:49 pm
Is there any hope for atea pharmaceuticals stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors....
November 4, 2021, 6:50 am
Is there any hope for atea pharmaceuticals stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors....
November 4, 2021, 6:50 am
Is there any hope for atea pharmaceuticals stock?
If its coronavirus pill project can't be salvaged, it'll be trouble for investors....
November 4, 2021, 6:50 am
Regeneron quarterly profit nearly doubles on strong demand for eczema drug
Regeneron pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust deman...
November 4, 2021, 6:42 am
Regeneron quarterly profit nearly doubles on strong demand for eczema drug
Regeneron pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust deman...
November 4, 2021, 6:42 am
Regeneron quarterly profit nearly doubles on strong demand for eczema drug
Regeneron pharmaceuticals Inc's third-quarter profit nearly doubled on Thursday, helped by robust deman...
November 4, 2021, 6:42 am
Supernus pharmaceuticals to acquire this pharmaceuticals company for $400 million
Supernus pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contra...
October 11, 2021, 1:44 pm
Supernus pharmaceuticals to acquire this pharmaceuticals company for $400 million
Supernus pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contra...
October 11, 2021, 1:44 pm
Supernus pharmaceuticals to acquire this pharmaceuticals company for $400 million
Supernus pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contra...
October 11, 2021, 1:44 pm
Shareholder alert: ademi llp investigates whether adamas pharmaceuticals, inc. has obtained a fair price in its transaction with supernus
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio...
October 11, 2021, 1:37 pm
Shareholder alert: ademi llp investigates whether adamas pharmaceuticals, inc. has obtained a fair price in its transaction with supernus
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio...
October 11, 2021, 1:37 pm
Shareholder alert: ademi llp investigates whether adamas pharmaceuticals, inc. has obtained a fair price in its transaction with supernus
MILWAUKEE, Oct. 11, 2021 /PRNewswire/ -- Ademi LLP is investigating Adamas (Nasdaq: ADMS), for possible breaches of fiduciary duty and other violatio...
October 11, 2021, 1:37 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical<...
October 11, 2021, 12:30 pm
Ocular therapeutix™ announces fda approval of supplemental new drug application (snda) for dextenza® (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use for the treatment of ocular itchi
BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical<...
October 11, 2021, 12:30 pm